Day: November 20, 2023

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the 35th Annual Piper Sandler Healthcare Conference in New York City on Thursday, November 30th, at 1:30 pm ET.   A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases....

Continue reading

OTC Markets Group Welcomes d’Amico International Shipping SA to OTCQX

NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced d’Amico International Shipping SA (Euronext STAR Milan: DIS; OTCQX: DMCOF), an international marine transportation company operating in the product tanker market, has qualified to trade on the OTCQX® Best Market. d’Amico International Shipping upgraded to OTCQX from the Pink® market. d’Amico International Shipping SA begins trading today on OTCQX under the symbol “DMCOF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on...

Continue reading

DAVIDsTEA Expands Wholesale Channel into U.S.

Initial launch of four flavours across Stop & Shop supermarket chain MONTREAL, Nov. 20, 2023 (GLOBE NEWSWIRE) — DAVIDsTEA Inc. (TSX-Venture: DTEA) (“DAVIDsTEA” or the “Company”), a leading tea merchant in North America, announced today its initial expansion into the U.S. wholesale market. DAVIDsTEA recently launched four flavours of premium tea sachets at 150 Stop & Shop supermarket stores of the 400-plus locations in the northeastern U.S. This regional chain of grocery stores operates throughout Massachusetts, Connecticut, Rhode Island, New York and New Jersey.  The curated offering dedicated to Stop & Shop buyers includes best-selling flavours such as the sleep-aid Valerian Nights, classic Cream of Earl Grey (organic), herbal, caffeine-free Forever Nuts, and herbal, caffeine-free Cold 911 (organic). They rank among...

Continue reading

ValOre Initiates Comprehensive Metallurgical Testwork Program at Pedra Branca

Figure 1 Figure 1: Long section of the Esbarro Deposit, showing location of the metallurgical twin holes sampled to form the Chromitite, Fresh and Weathered composite samples that will be subject to the testwork program. Dashed red line represents the modeled weathering surface, with approximately 45% of the 2022 Inferred Resource* at the Esbarro deposit modeled within the Weathered domain. VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) — ValOre Metals Corp. (“ValOre”; TSX‐V: VO; OTCQB: KVLQF; Frankfurt: KEQ0, “the Company”) today initiated a broad and comprehensive metallurgical testwork program for ValOre’s 100%-owned Pedra Branca Platinum Group Elements (“PGE”, “2PGE+Au”) Project (“Pedra Branca”) in northeastern Brazil. Thiago Diniz, Exploration Manager, ValOre Metals Corp., stated: “This metallurgical testwork...

Continue reading

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors. Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance. “We are thrilled to welcome Owen to the board of directors and leverage his experience across capital markets and pivotal business development opportunities,”...

Continue reading

Global Helium Corp. Confirms Second Helium Well Drilled and Cased in Alberta and Appoints New Director

CALGARY, Alberta, Nov. 20, 2023 (GLOBE NEWSWIRE) — Global Helium Corp. (“HECO” or the “Company“) (CSE: HECO, OTC: HECOF) today confirms that the Company has drilled and cased its second helium well at 10-08-12-04W4 (“10-08”), targeting the Beaverhill Lake zone and situated on the farm-in land block of Perpetual Energy Inc. (TSX: PMT) (“Perpetual”) within the Manyberries helium trend in Southeastern Alberta. HECO will proceed to testing of the 10-08 well before the end of November, which has also triggered the option to lease agreement as previously announced on January 10, 2023. Board Appointment HECO is also pleased to announce the appointment of Mr. Robert Nathan to the Company’s Board of Directors. Mr. Nathan is an attorney and investor with extensive experience in venture formation and capital raising,...

Continue reading

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy Volunteers Study – – Company Expects to Initiate Phase 2b Study in Mid-2024 – CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that clinical proof-of-concept has been achieved in the Phase 2a portion of a study of investigational pyruvate kinase (PK) activator AG-946 as a potential treatment for anemia in adults with lower-risk myelodysplastic syndromes (LR-MDS). Four of the 10 patients with low transfusion burden (LTB) achieved the transfusion independence endpoint, and one of the 22 patients...

Continue reading

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and tumor status; two patients from Cohort 2 remain alive beyond two years Additional enrolled patients await dosing with completion of enrollment in Cohort 3 expected in 2023 and long-term follow up to be presented at medical meetings in 2024 NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented data demonstrating that all patients treated with INB-200 who completed mandated doses have exceeded a progression-free survival (PFS) of seven months to date. This survival data shows the potential of IN8bio’s...

Continue reading

Osino Announces Wide, High Grade Au Assay Results From Shallow Infill Drilling at Twin Hills Gold Project, Namibia

Figure 1: Selected assays from the infill program at Bulge Figure 2: Section across the Infill Drilling Block at Bulge Figure 3: Selected assays from the infill program at Bulge and THC Highlights Completed reverse-circulation (“RC”) drilling of 110 boreholes at the Bulge pit at tight 12.5 x 12.5m spacing over an area covering the 1st year of open pit mining. 13 of 110 assay results are still outstanding with final results expected before end of November 2022. The program objective is to convert the first 2 years of mining from Indicated to Measured mineral resource category and to confirm and upgrade the Twin Hills Mineral Resource Estimate (“MRE”). Assay results received to date have returned wide and high-grade intercepts, including: OKRG0139: 102m @ 1.50g/t Au (21 – 123m) OKRG0122: 100m @ 1.37g/t Au (18 –...

Continue reading

Gritstone bio to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: 6th Annual Evercore ISI HealthCONx Conference (Fireside Chat)Presentation Date and Time: Wednesday, November 29, 2023 at 10:00am ETSpeaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive OfficerLocation: Miami, FL 35th Annual Piper Sandler Healthcare Conference (Fireside Chat)Presentation Date and Time: Thursday, November 30, 2023 at 10:00am ETSpeaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive OfficerLocation: New York, NY First Annual Goldman Sachs Catalyst Clinic (Fireside Chat)Presentation Date and Time: Tuesday,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.